Non-invasive Optical Imaging of Muscle Pathology in mdx Mice Using Cathepsin Caged Near-Infrared Imaging
- First Online:
- Cite this article as:
- Baudy, A.R., Sali, A., Jordan, S. et al. Mol Imaging Biol (2011) 13: 462. doi:10.1007/s11307-010-0376-z
- 552 Downloads
To develop a reliable live-animal imaging method for monitoring muscle pathology in mouse models of myopathy.
A caged near-infrared Cathepsin B (CTSB) substrate, ProSense 680, is evaluated in the dystrophin deficient mdx mice, a genetic homologue of Duchenne muscular dystrophy via optical imaging.
We show high levels of infrared signal in dystrophic muscle relative to healthy muscle at 24 h post-injection. Imaging for CTSB presence revealed localization to inflammatory infiltrates and regenerating muscle fibers. A time series myotoxin-induced muscle injury experiment showed that CTSB activity and its mRNA levels peaked at the interface between inflammation and myoblast fusion stage of recovery. Prednisone treatment in mdx mice resulted in decreased CTSB activity and increased grip strength in forelimbs and hindlimbs.
Optical imaging of CTSB activity is an ideal method to sensitively monitor inflammation, regeneration, and response to therapy in myopathic skeletal muscle.
Key wordsLive optical imaging Duchenne muscular dystrophy mdx Cathepsin B Muscle inflammation
Duchenne muscular dystrophy
Pre-clinical trials in animal models of muscle disease are a critical step in drug development. The most widely used genetic and biochemical model for Duchenne muscular dystrophy (DMD) is the mdx mouse [1, 2, 3]. However, it has a relatively mild disease phenotype compared to the progression of disease seen in human patients, and so establishing reliable and sensitive outcome measures for pre-clinical drug trials using this model has been challenging.
The availability of live-animal imaging accelerates the discovery of effective therapeutics in pre-clinical and clinical trials because it can deliver a variety of useful patho-physiological information in a longitudinal manner. Magnetic resonance imaging has been the primary imaging modality successful at detecting muscle pathology, but it has several limitations including cost, sensitivity for changes in muscle tissue, speed of operation, and compliance of awake children [4, 5, 6]. An alternative approach is the use of optical probes, such as caged near-infrared enzyme substrates, where imaging can be done using optical systems .
In DMD, dystrophin deficiency results in plasma membrane abnormalities, with increased susceptibility to contraction-induced myofiber damage, and bouts of myofiber degeneration and regeneration [1, 8]. Inflammatory cells are a feature of dystrophic muscle, although the muscle is heterogeneous, with different regions showing degeneration, regeneration, and inflammation . In fact, tissue heterogeneity is a major limitation in using muscle biopsies to monitor efficacy of pre-clinical and clinical trials. Since regeneration and inflammation are critical disease components in DMD, the identification of an optical probe reflecting both of these processes would have the potential to be a sensitive and reliable surrogate biomarker relaying overall disease status within the muscle tissue.
The cathepsins are a family of 11 proteases that are expressed in most cell types and generally become cleaved and activated in low pH environments such as in the lysosomes . Cathepsin B (CTSB) is a cysteine protease that has previously been shown to be upregulated in DMD patient muscle, primarily localizing to macrophage infiltrating areas [11, 12]. CTSB is initially translated as an inactive 44 kDa precursor protein, but can be activated into a mature 33 kDa single-chain enzyme . CTSB is highly upregulated in activated fusing myoblasts and hypothesized to be a major contributor to the process of extracellular matrix remodeling, which is an essential step in muscle regeneration .
Here, we investigate the use of a CTSB substrate as a live-animal imaging method to assess muscle pathology. We show that optical imaging of CTSB enzyme activity using a caged near-infrared substrate (ProSense 680) is capable of effectively detecting muscle inflammation, regeneration, and response to therapy in the mdx model via optical imaging.
Materials and Methods
Patient Expression Biopsies
DMD patient populations in this study were drawn from a referral population. Flash-frozen muscle biopsies from patients with a tentative diagnosis of muscular dystrophy were sent to the Dr. Hoffman’s laboratory at Children’s National Medical Center, Washington DC. All biopsies were subjected to a standardized set of biochemical and histological assays, including immunostaining for dystrophin, alpha-sarcoglycan and merosin, and immunoblotting for dystrophin and dysferlin. All samples were analyzed under CNMC IRB protocol #2405 which has been reviewed and approved by the Office for the Protection of Human Subjects at Children’s National Medical Center. Dystrophin immunostaining and mRNA expression profiling were performed as described previously [15, 16] and analysis criteria was set to only include patients over 2 years of age.
C57bl/10ScSn-Dmdmdx/J (mdx) and control C57bl/10 (bl10) mice were purchased from Jackson Laboratory (Bar Harbor, ME) and all animal experiments were conducted in accordance with our IACUC guidelines under approved protocols.
Five-week-old mdx and bl10 mice that underwent optical imaging were first put under gas anesthesia using 4% isofluorane and 0.5 L/min 100% oxygen, placed inside an Optix MX2 Imager (ART) scanning chamber, and then anesthesia was maintained with 2% isofluorane and 0.5 L/min oxygen through a nose cone to the mice. The floor of the scanning chamber in which the mouse lies was heated in order to maintain normal physiological body temperatures. Hair covering areas to be scanned was removed with Nair. The plane of scanning was kept consistent between mice at the level immediately above the forelimbs. Mice underwent intraperitoneal (I.P.) injection with 0.75 nmol or 1.5 nmol of ProSense 680 (VisEn Medical), both prepared in a total volume of 150 μl phosphate-buffered saline (PBS). Areas of scanning were defined with a polygonal selection tool, then a 670 nm excitation laser was used for probe excitation at a 1.5-mm camera resolution in the whole body scanning experiments (n = 2/group), and at a 0.5-mm camera resolution in skeletal limbs (n = 3/group); emissions were collected from a 700-nm long-pass filter. After scanning, the mice were allowed to recover under 0.5 L/min oxygen. Optical-imaging intensities from all experiments were normalized to account for differences in scanning laser power, integration times, and scanning area selected between mice using Optiview 2.0 software.
Histology and Immunofluoresence
Quadriceps from mdx mice were isolated and frozen in liquid nitrogen-cooled isopentane, 8-μm frozen sections were prepared, and unfixed cryosections from ProSense-injected mice were scanned with a 635-nm excitation laser, and then subsequently stained with Hematoxylin and Eosin (H&E). Notexin-injured gastrocnemious muscles (see below) from bl10 mice were isolated and sectioned in the same manner, blocked in 10% horse serum (HS) diluted in PBS for 30 min, then incubated with Hoechst dye (Sigma Aldrich, 1:10,000), anti-laminin (Sigma Aldrich, 1:200), anti-embryonic myosin heavy-chain (University of Iowa Hybridoma Bank, 1:200), and anti-F4/80 (Serotec, 1:200) antibodies for 2 h at room temperature. The sections were washed three times with PBS, and then Cy2 (Jackson Immunoresearch, 1:500) and Alexafluor: 546, 633 (Invitrogen, 1:500) secondary antibodies were prepared in 10% HS diluted in PBS and applied for 1 h, then the sections were washed three times with PBS, and mounted with permount (Fisher Scientific). The sections were visualized using a LSM 510 confocal microscope (Zeiss).
mRNA profiles were analyzed for CTSB expression from a previously published study in which cardiotoxin was administered via intramuscular (I.M.) injection into the gastrocnemious muscle of bl10 mice . For the in vitro experiments notexin (Latoxin) was prepared at a concentration of 4 μg/ml in 70 μl of 0.9% NaCl and administered via I.M. injection into the right medial region of the gastrocnemious muscle of bl10 mice, and 0.9% NaCl was administered to the contralateral leg in the same region. Mice were divided into post-notexin injection days 1, 3, 5, and 14 subsets (n = 3/group) and all received a single injection I.P. of 1.5 nmol ProSense 680 24 h prior to imaging.
Eight-week-old mdx mice were split into untreated and prednisone treated groups (n = 3/group); the treated group received prednisone in time-release pellets (Innovative Research, 1 mg/kg), which were implanted subcutaneously to establish continuous drug delivery. After 3 weeks of administration, all mice were scanned for baseline levels of optical intensity, injected with 1.5 nmol of ProSense I.P, then 24 h later, both forelimbs and hindlimbs were scanned at 0.5-mm resolution and quantified using Optiview software. Grip strength was assessed using a grip-strength meter (Columbus instruments, Columbus, Ohio). Five successful hindlimb- and forelimb-strength measurements were recorded over a period of 2 min. The grip-strength measurements were collected in the morning hours over a 5-day period; the maximum values of each day over the 5-day period were used for subsequent analysis. Both grip strength and optical-imaging intensities were normalized directly to body weight.
Sample size calculations used a student’s t distribution to determine the number of mice per group needed to detect a significant difference between untreated and prednisone chronic treatment. The same method was used to determine sample sizes necessary to detect a significant difference in normalized forelimb/hindlimb measurements. All calculations assumed an alpha level of 0.05 and a power level of 80%.
Cathepsin B Shows High Expression in Duchenne Muscular Dystrophy Patient Muscle
Thirteen muscle biopsies from DMD patients and six biopsies from non-dystrophic control patients were evaluated by microarray transcriptional analysis, then queried for four CTSB probe sets, which represented the entire range of CTSB transcripts (see Supplementary Fig. 1 online). Twelve of the 13 DMD biopsies had upregulated CTSB levels in at least one of the four probe sets, and the majority of biopsies had upregulated CTSB levels in at least three of the four probe sets. DMD patient biopsy three was the primary outlier in the analysis, since CTSB was entirely downregulated. Five of the six non-dystrophic control group biopsies were downregulated for CTSB transcript, with only control patient biopsy six showing upregulation.
I.P. Injection of Caged Near-Infrared CTSB Substrate Detects Cathepsin Activity in Dystrophic Muscle
ProSense 680 is a small peptide substrate for activated CTSB . When cleaved by the CTSB enzyme, two caged fluorophores are released, with peak excitation at 680 nm, and emission in the near-infrared range (700 nm). Intraperitoneal injection of 1.5 nmol or 0.75 nmol ProSense 680 was done in 5-week-old wild-type bl10 and dystrophin-deficient mdx mice. Serial optical whole body scanning at a 1.5-mm camera step resolution demonstrated near-infrared signal in the liver and bladder at 6 h that was similar between dystrophic and control mice (see Supplementary Fig. 2a online). Signal corresponding to limb muscle was observed more specifically in the dystrophic mice with a plateau at 24–48 h. The average total limb photon intensity was quantified for both bl10 and mdx mice that were injected with either 1.5 or 0.75 nmol over time (see Supplementary Fig. 2b online).
Myotoxin-Induced Regeneration Stimulates CTSB Transcription, with Peak at Myoblast/Myotube Transition
Therapeutic Response can be Successfully Evaluated in the mdx Mouse with CTSB Imaging
Statistical Analysis Demonstrates Excellent Sensitivity in Detecting Strain and Drug Treatment Differences
Sample size calculations comparing forelimb and hindlimb between mdx and bl10 mice
N needed per group to detect a significant difference between mice strains
Mean total photon counts/mm2 ± SD
Mean total photon counts/mm2 ± SD
8,048.33 ± 977.08
2,645.67 ± 1,129.37
14,866.67 ± 2,920.73
8,354.17 ± 2,360.29
Sample-size calculations comparing untreated with prednisone
N needed per group to detect a significant treatment difference
Mean total photon counts/mm2 ± SD
Mean total photon counts/mm2 ± SD
7,005.0 ± 977.8
3,521.4 ± 911.6
12,481.7 ± 1,937.7
9,240.2 ± 1,722.8
Our goal was to define an optical-imaging method that could comprehensively capture muscle pathology in the mdx model, so as to improve the effectiveness of monitoring therapeutic intervention in pre-clinical studies. Since we wanted to encompass the widest range of the disease processes possible, we selected CTSB as our enzymatic marker since it reports on multiple key pathological events relevant to muscle injury. CTSB is secreted by macrophages and activated myoblasts to support the clearance of degenerating injured fibers, as well as promote regeneration via signaling for myoblast fusion [14, 19, 20]. It has already been demonstrated that CTSB protein levels are upregulated in DMD patients as well as in mouse xenograft models, and we further validate this by showing that four encompassing probe sets of the CTSB transcript population are also strongly upregulated (see Supplementary Fig. 1 online) [11, 12]. From the three DMD biopsies that demonstrated the lowest relative levels of CTSB (DMD 3, DMD 4, DMD 11), all had mild histological features such as larger fiber sizes, and minimal amounts of degenerating and regenerating fibers.
ProSense 680 is a commercial near-infrared probe from VisEn Medical and is highly specific for activated CTSB activity. It is normally optically quiescent, but upon reaching areas of activated CTSB, it becomes enzymatically cleaved and emits an intense near-infrared signal. We injected a single 0.75-nmol or 1.5-nmol dose of ProSense 680 I.P. to 5-week-old mdx and bl10 mice; this age group was selected because mdx mice show peak fiber degeneration and regeneration between 4–10 weeks (see Supplementary Fig. 2 online). Sequential whole body 1.5-mm camera resolution infrared imaging revealed that both bl10 and mdx mice had active CTSB in the liver and bladder; however, activity was consistently detected at higher levels in mdx limbs compared to bl10 at the 1.5-nmol dose. ProSense levels declined over the course of 7 days, eventually reaching near baseline values, indicating clearance of the probe.
Having determined the peak dose and time point to detect differences in CTSB activity between mdx and bl10 limb muscle, we performed high-resolution camera (0.5 mm) imaging of only the forelimbs and hindlimbs 24 h later (Fig. 1a). The CTSB levels were increased in mdx tissue over bl10, indicating higher levels of inflammation and regeneration. Moreover, the higher levels of CTSB activity in mdx forelimbs over bl10 forelimbs (3.1-fold increase) compared to mdx forelimbs over bl10 hindlimbs (1.9-fold increase) suggested more relative pathology in the forelimbs. Interestingly, this finding is supported by functional grip-strength studies, which clearly demonstrate a greater deficit in grip strength between mdx and bl10 mice in the forelimbs over the hindlimbs . Taken together, this suggests that CTSB activity could be inversely related to grip strength. Cryosectioning of quadriceps taken from mdx mice that had been injected with ProSense revealed CTSB activity localized specifically to areas of myofiber remodeling (inflammation and regeneration) (Fig. 1b).
We have defined a sensitive method for detecting dystrophic pathology; we therefore wanted to extend its applicability for detecting broader types of muscle injury. Myotoxins such as cardiotoxin and notexin are isolated from snake venom and are highly damaging to myofibers. Intramuscular injection of myotoxins has been shown to induce controlled muscle injury, and, therefore, is useful for studying stage-specific processes in muscle damage and regeneration [22, 23]. Cardiotoxin injection into the gastrocnemious of bl10 mice followed by microarray transcriptional profiling and querying for CTSB revealed that mRNA levels of the enzyme were highest between days 2–5, post injury, with a peak at day 3 (Fig. 2a). Mice that received an intramuscular notexin injection into their right gastrocnemious and were imaged showed an extraordinary amount of activated CTSB at day 1 (Fig. 2b); the levels observed here were more than double that of the mdx hindlimb activity shown earlier, demonstrating the severity of acute damage. The peak amount of activated CTSB occurred at day 3, which paralleled mRNA production. By day 14, CTSB approached comparable levels to the saline-injected leg, reflecting the completion of successful myoblast fusion and clearance of infiltrating inflammatory cells. The saline-injected contralateral control leg showed a similar progression in CTSB activity over time, with a peak amount of damage also occurring at day 3, but at much lower levels.
Upon histological investigation of gastrocnemious muscles from Notexin-injured mice, we found co-localization of the CTSB inactive precursor protein exclusively in infiltrating macrophages, as demonstrated by co-localization between CTSB antibody and F4/80 (Fig. 3). Interestingly, upon imaging of ProSense and embryonic Myosin, heavy-chain, active CTSB was also detected in both infiltrating monocytes and regenerating fibers (Fig. 4). These results substantiate our findings in the quadriceps of 5-week-old mdx mice, in that active CTSB is highly localized to areas of myofiber damage, and demonstrate its association with muscle repair, inflammatory, and remodeling processes.
The only effective treatment for DMD discovered to date is glucocorticoids, such as prednisone . Granted that glucocorticoids are ridden with numerous long-term treatment side effects, they are known to reduce both inflammation and excessive muscle degeneration in the short term. We tested our caged CTSB optical method to gauge prednisone’s therapeutic effects by administering it for a total of 3 weeks to mdx mice in a continuous release pellet, and then performed functional grip-strength tests and optical imaging (Fig. 5). Significant decreases of CTSB activity were measured in both the hindlimbs and forelimbs of prednisone-treated mice, and were accompanied by increases in grip strength (Fig. 5). These data clearly indicate that a decrease in CTSB activity is reflected in an increase in grip-strength measurements at the functional level. The assay described is highly sensitive and specific, requiring only a few animals to see differences between affected and wild-type, or between drug-treated and control dystrophic animals (Tables 1 and 2).
Overall, we found that, under the conditions described, ProSense 680 is a highly effective tool for evaluating in vivo assessments of muscle damage, and as a measure of efficacy for drugs designed to reduce inflammation and damage in dystrophic muscle in pre-clinical trials. In the clinic, Optical imaging is beginning to be used more frequently since it doesn’t depend on radioactive substances or ionizing radiation, yet provides functional data in a cost-effective manner [25, 26]. The detection of probes using optical imaging also exhibits excellent sensitivity (nmol–pmol range). However, in order to obtain clinically useful results, optical systems and their corresponding probes need to be optimized for monitoring deep tissues due to constraints related to light transmittance and scattering. It would be interesting to see if more powerful therapeutic treatments (e.g., exon skipping, adenovirus gene replacement) could be evaluated using this methodology, and further, if this technology could be applied to DMD patients to gather rapid information on disease progression.
Andreas R. Baudy is a pre-doctoral student in the Molecular Medicine Program of the Institute for Biomedical Sciences at the George Washington University. This work is from a dissertation to be presented to the above program in partial fulfillment of the requirements for the Ph.D. degree.
Dr. Nagaraju is supported by National Institute of Health (RO1-AR050478 and 5U54HD053177), Foundation to Eradicate Dystrophy, Muscular Dystrophy Association, The Myositis Association and US Department of Defense (W81XWH-05-1-0616).
Dr. Hoffman is supported by National Institute of Health (RO1-5U54HD053177) and the US Department of Defense (W81XWH-05-1-0616).
Conflict of Interest
The authors declare that they have no conflict of interest.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.